News
COCP
1.500
0.00%
0.000
Cocrystal Pharma Inc <COCP.OQ> expected to post a loss of 60 cents a share - Earnings Preview
Cocrystal Pharma Inc expected to post a loss of 60 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 27. LSEG's mean analyst estimate for Cocrystal Pharma. Inc is for the period ending December 31 2023.
Reuters · 3d ago
Weekly Report: what happened at COCP last week (0318-0322)?
Weekly Report · 3d ago
Cocrystal Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 03/20 10:58
HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Benzinga · 03/20 10:47
Cocrystal Pharma’s Promising Influenza A Treatment Garners Buy Rating from Analyst Ram Selvaraju
TipRanks · 03/20 10:26
Cocrystal Pharma Advances Influenza A Treatment Development
TipRanks · 03/19 12:42
Weekly Report: what happened at COCP last week (0311-0315)?
Weekly Report · 03/18 10:58
Weekly Report: what happened at COCP last week (0304-0308)?
Weekly Report · 03/11 10:56
Weekly Report: what happened at COCP last week (0226-0301)?
Weekly Report · 03/04 10:58
Weekly Report: what happened at COCP last week (0219-0223)?
Weekly Report · 02/26 11:09
Weekly Report: what happened at COCP last week (0212-0216)?
Weekly Report · 02/19 11:11
Weekly Report: what happened at COCP last week (0205-0209)?
Weekly Report · 02/12 11:02
Weekly Report: what happened at COCP last week (0129-0202)?
Weekly Report · 02/05 11:09
Weekly Report: what happened at COCP last week (0122-0126)?
Weekly Report · 01/29 10:59
Weekly Report: what happened at COCP last week (0115-0119)?
Weekly Report · 01/22 11:03
Weekly Report: what happened at COCP last week (0108-0112)?
Weekly Report · 01/15 11:00
Cocrystal Pharma Inc: Current report
Press release · 01/08 16:13
Weekly Report: what happened at COCP last week (0101-0105)?
Weekly Report · 01/08 11:03
Cocrystal Pharma Inc: Current report
Press release · 01/05 02:59
Cocrystal Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/03 13:56
More
Webull provides a variety of real-time COCP stock news. You can receive the latest news about Cocrystal Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About COCP
Cocrystal Pharma, Inc. is a biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. It is developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It also uses advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. The Company’s pipeline CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus replication machinery is targeted.